Effect of intravitreal Bevacizumab on macular edema secondary to retinal vascular occlusion

Abstract

Objective: To find out the effect of intravitreal injection of Bevacizumab on central macular thickness (CMT) and best corrected visual acuity (BCVA) in cases of retinal vascular occlusion (RVO). Material and method: All the patients of RVO treated at our institute over a period of 1 year, with a central macular thickness of more than 250µ were included in the study. Intravitreal injection of Bevacizumab was given and the CMT and BCVA were measured after a control period of 1 month. The injection was repeated at intervals of 1.5 months if decrease in CMT was less than 30%. Result: Out of the total 78 patients there was a significant improvement in BCVAin 58 patients. There was a significant decrease in central macular thickness in all of them. Conclusion: Anti-VEGF agent Bevacizumab causes significant reduction in central macular thickness and improves BCVA in cases of macular edema secondary to retinal vascular occlusion.